Ivermectin Not Effective in Stopping Severe COVID, Study Finds

Feb. 22, 2022 — Ivermectin, the controversial anti-parasitic drug, doesn’t assist deal with gentle to average COVID-19, one other new examine has discovered.

“The examine findings don’t help using ivermectin for sufferers with COVID-19,” researchers mentioned within the examine revealed final week in JAMA Internal Medicine.

The trial befell at 20 public hospitals and a COVID-19 quarantine middle in Malaysia between May 31 and Oct. 25.

Among 241 sufferers who obtained ivermectin, 52 developed extreme COVID-19, in comparison with 43 of 249 sufferers who didn’t take the drug.

The individuals studied, who have been on common 62 years previous and have been 55% ladies, have been randomly assigned to obtain both a 5-day course of ivermectin plus normal care or normal care alone.

No Difference by Vaccine Status

The researchers additionally checked out smaller teams of individuals within the examine to see if there have been variations in whether or not they have been vaccinated. They mentioned that evaluation was “unremarkable.”

Just greater than half of members (51.8%) have been totally vaccinated with two doses of COVID-19 vaccines. Among the vaccinated sufferers, 17.7% within the ivermectin group and 9.2% within the management group developed extreme illness.

Ivermectin and COVID

While the FDA has not authorized ivermectin to deal with COVID-19, medical doctors proceed to prescribe the cheap and extensively accessible antiparasitic drug anyway. There is little proof the drug is efficient in treating COVID-19, however it has been embraced by anti-vaccine advocates as a useable various.

There have been stories of individuals changing into hospitalized after taking ivermectin, and the FDA has even warned in opposition to its use.

The authors of the brand new examine acknowledge the controversy: “Although some early scientific research prompt the potential efficacy of ivermectin within the therapy and prevention of COVID-19, these research had methodologic weaknesses.”